ZLc-002

• UNSPSC Description:

  ZLc-002 is a selective inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain. ZLc-002 can be used for the research of anxiety disorder and inflammation[1][2][3].

• Target Antigen:

  Others

• Type:

  Reference compound

• Related Pathways:

  Others

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/zlc-002.html

• Solubility:

  10 mM in DMSO

• Smiles:

  COC(CC(N[C@H](C(C)C)C(OC)=O)=O)=O

• Molecular Weight:

  231.25

• References & Citations:

  [1]Ni HY, et al.Dissociating nNOS (Neuronal NO Synthase)-CAPON (Carboxy-Terminal Postsynaptic Density-95/Discs Large/Zona Occludens-1 Ligand of nNOS) Interaction Promotes Functional Recovery After Stroke via Enhanced Structural Neuroplasticity. Stroke. 2019 Mar;50(3):728-737. |[2]Zhu LJ, et al. nNOS-CAPON blockers produce anxiolytic effects by promoting synaptogenesis in chronic stress-induced animal models of anxiety. Br J Pharmacol. 2020 Aug;177(16):3674-3690.|[3]Zhu LJ, et al.CAPON-nNOS coupling can serve as a target for developing new anxiolytics. Nat Med. 2014 Sep;20(9):1050-4. doi: 10.1038/nm.3644. Epub 2014 Aug 17.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1446971-41-0